Targeting the MEK and STAT3 Pathways in Combination With PD1 Blockade Immunotherapy in KRAS-mutant Pancreatic Cancer

被引：0
|
作者：
Mehra, S. [1 ]
Lamichhane, P. [1 ,2 ]
Messaggio, F. [1 ]
Dai, X. [1 ]
Dosch, A. [1 ]
Willobee, B. [1 ]
Srinivasan, S. [1 ]
VanSaun, M. N. [1 ,3 ]
Nagathihalli, N. [1 ,3 ]
Merchant, N. [1 ,3 ]
机构：
[1] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA
[2] LECOM Sch Dent Med, Bradenton, FL USA
[3] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA
来源：
PANCREAS | 2019年 / 48卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1490 / 1490
页数：1
相关论文
共 50 条
  • [1] Combination Immunotherapy with MEK Inhibitor for Treatment of Kras-Mutant Lung Cancer in Animal Model
    Lee, Jong Woo
    Zhang, Yu
    Choi, Justin
    Sharma, Roshan
    Park, Hee Sun
    Kaftan, Edward
    Papadimitrakopoulou, Vassiliki
    Herbst, Roy
    Koo, J. Peter
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1319 - S1319
  • [2] Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
    Miyazaki, Satoru
    Kitazawa, Masato
    Nakamura, Satoshi
    Koyama, Makoto
    Yamamoto, Yuta
    Hondo, Nao
    Kataoka, Masahiro
    Tanaka, Hirokazu
    Takeoka, Michiko
    Komatsu, Daisuke
    Soejima, Yuji
    MOLECULAR ONCOLOGY, 2025, 19 (02) : 377 - 390
  • [3] MET-Dependent Activation of STAT3 as Mediator of Resistance to MEK Inhibitors in KRAS-Mutant Lung Cancer
    Lazzari, Chiara
    Karachaliou, Niki
    Verlicchi, Alberto
    Codony Servat, Caries
    Gimenez Capitan, Ana
    Codony Servat, Jordi
    Bertran-Alamillo, Jordi
    Molina Vila, Miguel Angel
    Chaib, Imane
    Ramirez Serrano, Jose Luis
    Cao, Peng
    De Marinis, Filippo
    Gregorc, Vanesa
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S527 - S527
  • [4] Combination inhibitor strategies targeting KRAS effector signaling in KRAS-mutant pancreatic cancer.
    Ozkan-Dagliyan, Irem
    Goodwin, Craig M.
    Bryant, Kirsten L.
    George, Samuel D.
    Lucas, Kelly
    Gautam, Prson
    Wennerberg, Krister
    Cox, Adrienne D.
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 68 - 68
  • [5] Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
    Herter-Sprie, Grit S.
    Koyama, Shohei
    Korideck, Houari
    Hai, Josephine
    Deng, Jiehui
    Li, Yvonne Y.
    Buczkowski, Kevin A.
    Grant, Aaron K.
    Ullas, Soumya
    Rhee, Kevin
    Cavanaugh, Jillian D.
    Neupane, Neermala Poudel
    Christensen, Camilla L.
    Herter, Jan M.
    Makrigiorgos, G. Mike
    Hodi, F. Stephen
    Freeman, Gordon J.
    Dranoff, Glenn
    Hammerman, Peter S.
    Kimmelman, Alec C.
    Wong, Kwok-Kin
    JCI INSIGHT, 2016, 1 (09)
  • [6] Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
    Deken, Marcel A.
    Gadiot, Jules
    Jordanova, Ekaterina S.
    Lacroix, Ruben
    van Gool, Melissa
    Kroon, Paula
    Pineda, Cristina
    Foppen, Marnix H. Geukes
    Scolyer, Richard
    Song, Ji-Ying
    Verbrugge, Inge
    Hoeller, Christoph
    Dummer, Reinhard
    Haanen, John B. A. G.
    Long, Georgina V.
    Blank, Christian U.
    ONCOIMMUNOLOGY, 2016, 5 (12):
  • [7] Inhibitor combinations targeting KRAS effector signaling in KRAS-mutant pancreatic cancer
    Cox, Adrienne D.
    Goodwin, Craig M.
    Bryant, Kirsten L.
    Dagliyan, Irem
    George, Samuel D.
    Lucas, Kelly E.
    Gautam, Prson
    Wennerberg, Krister
    Der, Channing J.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] MIF-induced stat3 activation promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
    Cheon, Seul-Ki
    Kim, Hwang-Phill
    Park, Ye-Lim
    Lee, Si Hyun
    Kang, Jun-Kyu
    Lim, Yoojoo
    Song, Sang-Hyun
    Han, Sae-Won
    Kim, Tae-You
    CANCER RESEARCH, 2017, 77
  • [9] Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
    Okumura, Shunsuke
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2014, 20 (16) : 4193 - 4199
  • [10] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Xiufeng Pang
    Mingyao Liu
    Chinese Journal of Cancer, 2016, 35 (11) : 571 - 573
12345